lenalidomide
Showing 1 - 25 of 662
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma (MZL)
- Odronextamab
- +2 more
-
Chiang Mai, ThailandChiang Mai University
Nov 20, 2023
Multiple Myeloma Trial in Canton (Lenalidomide)
Recruiting
- Multiple Myeloma
- Lenalidomide
-
Canton, OhioGabrail Cancer & Research Center
Oct 11, 2023
MDS Trial in Beijing (Lenalidomide, Azacitidine)
Not yet recruiting
- Myelodysplastic Syndromes
- Lenalidomide
- Azacitidine
-
Beijing, ChinaPeking union medical college hospital
Aug 16, 2023
Multiple Myeloma, Myeloma-Associated Amyloidosis Trial in Saint Louis (Selinexor, Lenalidomide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma
- Myeloma-Associated Amyloidosis
- Selinexor
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Apr 6, 2023
Multiple Myeloma Trial in Houston (Isatuximab, lenalidomide)
Not yet recruiting
- Multiple Myeloma
- Isatuximab
- lenalidomide
-
Houston, TexasM D Anderson Cancer Center
Mar 8, 2023
Advanced HCC Trial (Lenalidomide)
Not yet recruiting
- Advanced HCC
- Lenalidomide
- (no location specified)
Apr 16, 2023
Multiple Myeloma Trial in Augusta (Lenalidomide, Vitamin D - Intensified, Vitamin D - Therapeutic)
Not yet recruiting
- Multiple Myeloma
- Lenalidomide
- +2 more
-
Augusta, GeorgiaGeorgia Cancer Center at Augusta University
Apr 26, 2023
Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Epcoritamab
- Lenalidomide
- (no location specified)
Jan 20, 2023
Multiple Myeloma Trial in Worldwide (Elranatamab, Daratumumab, Lenalidomide)
Recruiting
- Multiple Myeloma
- Elranatamab
- +3 more
-
Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
- +7 more
Jan 9, 2023
Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)
Not yet recruiting
- Relapsed/Refractory Marginal Zone Lymphoma
- Orelabrutinib
- +3 more
-
Guangzhou, Guangdong, China
- +10 more
Oct 8, 2023
Multiple Myeloma Trial in Boston, Columbus (drug, biological, other)
Terminated
- Multiple Myeloma
- lenalidomide
- +3 more
-
Boston, Massachusetts
- +1 more
Nov 14, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Tampa (High Dose Methylprednisolone (HDMP), Ofatumumab,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- High Dose Methylprednisolone (HDMP)
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 12, 2023
Follicular Lymphoma Trial in Shanghai (lenalidomide, rituximab, parsaclisib)
Not yet recruiting
- Follicular Lymphoma
- lenalidomide
- +2 more
-
Shanghai, Shanghai, ChinaRuijin hospital, school of medicine, Shanghai jiao tong universi
May 10, 2023
Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin Trial in Madison (Bendamustine, Rituximab, Lenalidomide)
Completed
- Lymphoid Leukemia
- +2 more
- Bendamustine
- +2 more
-
Madison, WisconsinUniversity of Wisconsin
Jan 30, 2023
Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Tafasitamab
- +3 more
-
Cologne, GermanyUniversity of Cologne
Oct 14, 2022
Follicular Lymphoma Trial in Duarte, Irvine (procedure, other, biological, drug)
Not yet recruiting
- Follicular Lymphoma
- Biospecimen Collection
- +7 more
-
Duarte, California
- +1 more
Oct 27, 2023
Primary CNS Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)
Completed
- Primary Central Nervous System Lymphoma
- Rituximab
- +2 more
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 18, 2022
DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- PF-07901801
- +2 more
-
San Juan, Puerto RicoAuxilio Mutuo Cancer Center
Jan 19, 2023
Multiple Myeloma Trial in Nantong (Colchicine, Lenalidomide)
Recruiting
- Multiple Myeloma
- Colchicine
- Lenalidomide
-
Nantong, Jiangsu, ChinaAffiliated Hospital of Nantong University
Mar 25, 2023
Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL Trial in Houston (Mosunetuzumab, Polatuzumab vedotin, Tafasitamab)
Not yet recruiting
- Hodgkin Lymphoma
- +2 more
- Mosunetuzumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Nov 7, 2022
Newly Diagnosed Multiple Myeloma Trial in New York (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- Newly Diagnosed Multiple Myeloma
- Daratumumab
- +4 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Dec 29, 2022
Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia Trial in Houston (Laboratory Biomarker
Completed
- Alkylating Agent-Related Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Laboratory Biomarker Analysis
- Lenalidomide
-
Houston, TexasM D Anderson Cancer Center
Oct 18, 2022
Multiple Myeloma Trial in United States (Ixazomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Ixazomib
- +2 more
-
Duarte, California
- +9 more
Jan 11, 2023
Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,
Recruiting
- Cutaneous T-Cell Lymphoma
- +3 more
- Romidepsin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023